Sapitinib (AZD8931)

Catalog No.S2192 Batch:S219201

Print

Technical Data

Formula

C23H25ClFN5O3
Molecular Weight 473.93 CAS No. 848942-61-0
Solubility (25°C)* In vitro DMSO 95 mg/mL (200.45 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Sapitinib (AZD8931) is a reversible, ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 with IC50 of 4 nM, 3 nM and 4 nM in cell-free assays, more potent against NSCLC cell, 100-fold more selective for the ErbB family than MNK1 and Flt. Phase 2.
Targets
ErbB2 [1]
(Cell-free assay)		 EGFR [1]
(Cell-free assay)		 ErbB3 [1]
(Cell-free assay)
3 nM 4 nM 4 nM
In vitro

AZD8931 shows different potency to NSCLC and SCCHN cell lines. AZD8931 has high sensitivity to PC-9 cells (EGFR activating mutation) with GI50 of 0.1 nM and low activity to NCI-1437 cells with GI50 above 10 μM. AZD8931 exhibits more potency against phospho-EGFR, phospho-erbB2 and phospho-erbB3 in PE/CA-PJ41, PE/CA-PJ49, DOK and FaDu cells. [1]
In vivo

AZD8931 reveals antitumor activity in BT474c, Calu-3, LoVo, FaDu and PC-9 xenografts. AZD8931 could reduce p-Akt, Ki67 expression and p-ERK in BT474c xenografts following acute treatment. AZD8931 also causes induction of the M30 apoptosis marker. Furthermore, AZD8931 shows greater proapoptotic effect in LoVo xenografts. [1]

Protocol (from reference)

Kinase Assay:

[1]
  • Isolated kinase assays

    The intracellular kinase domains of human EGFR and erbB2 are cloned and expressed in the baculovirus/Sf21 system. The inhibitory activity of AZD8931 is determined with ATP at Km concentrations (0.4 mM for erbB2 and 2 mM for EGFR) using the ELISA method.
Cell Assay:

[1]
  • Cell lines

    Head and neck tumor cell lines (KYSE-30, OE21, PE/CA-PJ15, PE/CA-PJ34 (clone C12), PE/CA-PJ41 (clone D2), PE/CA-PJ49, DOK, Detroit562, RPMI2650, SCC-4, SCC-9, SCC-25, CAL 27, SW579, FaDu, Hs 840.T, KB, KYSE-450, and HEp-2, HN5) and NSCLC cell lines (PC-9,

  • Concentrations

    0.001-10 μM

  • Incubation Time

    96 hours

  • Method

    To determine the antiproliferative activity against cell lines grown in vitro, AZD8931 is tested in a panel of NSCLC and SCCHN cell lines. Cells are incubated for 96 hours with AZD8931 (0.001-10 μM). Viable cell number is determined by 4 hours of incubation with MTS Colorimetric Assay reagent and absorbance measured at 490 nm on a spectrophotometer.
Animal Study:

[1]
  • Animal Models

    BT474c, Calu-3, LoVo, FaDu and PC-9 xenografts in Swiss nude or severe combined immunodeficient (Charles River) mice.

  • Dosages

    6.25-50 mg/kg

  • Administration

    Gavage

Customer Product Validation

Data from [J Immunol, 2014, 192(2), 722-31]

Data from [Data independently produced by , , J Pathol, 2016, 239(3):320-34.]

Data from [Data independently produced by , , Oncol Rep, 2016, 36(2):1000-6]

Selleck's Sapitinib (AZD8931) has been cited by 50 publications

Identification of kinase modulators as host-directed therapeutics against intracellular methicillin-resistant Staphylococcus aureus [ Front Cell Infect Microbiol, 2024, 14:1367938] PubMed: 38590439
Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer [ Cell Death Dis, 2023, 14(8):532] PubMed: 37596261
Colorectal Cancer Patient-Derived 2D and 3D Models Efficiently Recapitulate Inter- and Intratumoral Heterogeneity [ Adv Sci (Weinh), 2022, e2201539] PubMed: 35652270
Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer [ BMC Cancer, 2022, 22(1):478] PubMed: 35501832
Cooperative induction of receptor tyrosine kinases contributes to adaptive MAPK drug resistance in melanoma through the PI3K pathway [ Cancer Rep (Hoboken, 2022, e1736] PubMed: 36251678
STAT3 mediated upregulation of C-MET signaling acts as a compensatory survival mechanism upon EGFR family inhibition in chemoresistant breast cancer cells [ Cancer Lett, 2021, 519:328-342] PubMed: 34348188
Probing the signaling requirements for naive human pluripotency by high-throughput chemical screening [ Cell Rep, 2021, 35(11):109233] PubMed: 34133938
Heterotypic cell-cell communication regulates glandular stem cell multipotency [ Nature, 2020, 584(7822):608-613] PubMed: 32848220
Heterotypic cell-cell communication regulates glandular stem cell multipotency [ Nature, 2020, 584(7822):608-613] PubMed: 32848220
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance [ Breast Cancer Res, 2020, 22(1):84] PubMed: 32771039

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.